Allergan to acquire Vitae Pharmaceuticals
DUBLIN, Ireland — Allergan plc plans to buy clinical-stage biotech firm Vitae Pharmaceuticals Inc. in a cash deal valued at $639 million. Allergan said the acquisition will bolster its dermatology product pipeline with the addition of VTP-43742, a Phase 2 orally active RORγt inhibitor for the potential treatment of psoriasis and other autoimmune disorders. The
